Efficacy and Safety of Erlotinib vs Vinorelbine/Cisplatin as Adjuvant Therapy for Stage IIIA EGFR Mutant NSCLC Patients

被引：3
|
作者：
Yue, D. [1 ]
Xu, S. [2 ]
Wang, Q. [3 ]
Li, X. [4 ]
Shen, Y. [5 ]
Zhao, H. [6 ]
Chen, C. [7 ]
Mao, W. [8 ]
Liu, W. [9 ]
Liu, J. [10 ]
Zhang, L. [11 ]
Ma, H. [12 ]
Li, Q. [13 ]
Yang, Y. [14 ]
Liu, Y. [15 ]
Chen, H. [16 ]
Wang, C. [1 ]
机构：
[1] Tianjin Med Univ, Canc Inst & Hosp, Canc Inst & Hosp, Tianjin, Peoples R China
[2] Harbin Med Univ, Canc Hosp, Harbin, Heilongjiang, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[4] Fourth Mil Med Univ, Tangdu Hosp, XiAn Hosp, Xian, Shaanxi, Peoples R China
[5] Qing Dao Univ, Hosp 1, Qingdao, Shandong, Peoples R China
[6] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[7] Fujian Med Univ, Union Hosp, Fuzhou, Fujian, Peoples R China
[8] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
[9] Jilin Univ, Bethune Hosp 1, Changchun, Jilin, Peoples R China
[10] Tumor Hosp Hebei Prov, Shijiazhuang, Hebei, Peoples R China
[11] Sun Yat Sen Univ, Canc Hosp, Guangzhou, Guangdong, Peoples R China
[12] Suzhou Univ, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China
[13] Sichuan Canc Hosp & Inst, Chengdu, Sichuan, Peoples R China
[14] Peking Univ, Canc Hosp, Beijing, Peoples R China
[15] Liaoning Canc Hosp, Shenyang, Tianjin, Peoples R China
[16] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Adjuvant therapy; Erlotinib; EGFR mutation;
D O I：
10.1016/j.jtho.2017.09.423
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA 16.04
引用
收藏
页码：S1789 / S1789
页数：1
相关论文
共 50 条
  • [41] Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC
    Lu, Kevin
    Woodward, Brian D.
    Boys, Joshua
    Onaitis, Mark
    Husain, Hatim
    CLINICAL LUNG CANCER, 2024, 25 (01) : e58 - e61
  • [42] The Safety and Efficacy of Aumolertinib in Advanced EGFR-mutant NSCLC Patients Who Were Intolerant to Osimertinib Treatment
    Zheng, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S646 - S647
  • [43] Osimertinib as adjuvant therapy in patients with resected EGFRm stage IB-IIIA NSCLC: updated results from ADAURA
    Grohe, C.
    Tsuboi, M.
    Wu, Y.
    John, T.
    Majem, M.
    Wang, J.
    Kato, T.
    Goldman, J.
    Kim, S.
    Yu, C.
    Vu, H.
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F.
    Urban, D.
    Stachowiak, M.
    Balanos, A.
    Huang, X.
    Herbst, R.
    Kern, J.
    PNEUMOLOGIE, 2023, 77 : S17 - S17
  • [44] Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
    Chen, Ping
    Yang, Qing
    Li, Yinfeng
    Jing, Xiaomei
    Chen, Jing
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [45] Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study
    Kreuter, M.
    Vansteenkiste, J.
    Fischer, J. R.
    Eberhardt, W.
    Zabeck, H.
    Kollmeier, J.
    Serke, M.
    Frickhofen, N.
    Reck, M.
    Engel-Riedel, W.
    Neumann, S.
    Thomeer, M.
    Schumann, C.
    De Leyn, P.
    Graeter, T.
    Stamatis, G.
    Zuna, I.
    Griesinger, F.
    Thomas, M.
    ANNALS OF ONCOLOGY, 2013, 24 (04) : 986 - 992
  • [46] Safety and efficacy of stereotactic body radiotherapy (SBRT) to oligoresidual sites combine with osimertinib in stage IV EGFR mutant NSCLC patients: A prospective pilot study
    Chen, Cheng
    Wang, Ying
    Liao, Siqin
    Zheng, Bin
    Chen, Chen
    Zeng, Bangwei
    Liao, Lianming
    Xu, Benhua
    Chen, Chun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Chemotherapy and Immunotherapy in Early-Stage NSCLC: Neoadjuvant vs Adjuvant Therapy
    Wakelee, Heather
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (12) : 648 - 651
  • [48] Neoadjuvant erlotinib in stage III NSCLC patients (pts) with activating EGFR mutations (EVENT trial).
    Inal, Cengiz
    Piperdi, Bilal
    Keller, Steven M.
    Halmos, Balazs
    Stoopler, Mark
    Limaye, Sewanti Atul
    Levy, Benjamin Philip
    Schneider, Bryan J.
    Kim, Mimi
    Sides, Jessica
    Perez-Soler, Roman
    Cheng, Haiying
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Efficacy of cisplatin plus vinorelbine adjuvant chemotherapy with split-dose administration of cisplatin after complete resection of stage II-IIIA non-small cell lung cancer
    Funaguchi, Norihiko
    Iihara, Hirotoshi
    Kaito, Daizo
    Gomyo, Takenori
    Sasaki, Yuka
    Yanase, Komei
    Endo, Junki
    Ito, Fumitaka
    Hirose, Chiemi
    Ohno, Yasushi
    Okura, Hiroyuki
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (04)
  • [50] ILLUMINATE: Efficacy and Safety of Durvalumab/ Tremelimumab and Chemotherapy in EGFR-Mutant NSCLC Following Progression on EGFR Inhibitors
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (10) : 8 - 9
12345